Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 217 to 224 of 224 entries
Sorted by: Best Match Show Resources per page
Further Evidence of Allergic Contact Dermatitis Caused by 2,2'-Methylenebis(6-tert-Butyl-4-Methylphenol) Monoacrylate, a New Sensitizer in the Dexcom G6 Glucose Sensor.

Dermatitis : contact, atopic, occupational, drug

Mowitz M, Lejding T, Ulriksdotter J, Antelmi A, Bruze M, Svedman C.
PMID: 34115662
Dermatitis. 2021 Jun 11; doi: 10.1097/DER.0000000000000767. Epub 2021 Jun 11.

BACKGROUND: Since the spring of 2020, we have seen several patients experiencing severe allergic contact dermatitis (ACD) from the Dexcom G6 glucose sensor after the composition of the sensor's adhesive patch had been changed. We have previously reported the...

Cite
Mowitz M, Lejding T, Ulriksdotter J, et al. Further Evidence of Allergic Contact Dermatitis Caused by 2,2'-Methylenebis(6-tert-Butyl-4-Methylphenol) Monoacrylate, a New Sensitizer in the Dexcom G6 Glucose Sensor. Dermatitis. 2021;doi: 10.1097/DER.0000000000000767.
Mowitz, M., Lejding, T., Ulriksdotter, J., Antelmi, A., Bruze, M., & Svedman, C. (2021). Further Evidence of Allergic Contact Dermatitis Caused by 2,2'-Methylenebis(6-tert-Butyl-4-Methylphenol) Monoacrylate, a New Sensitizer in the Dexcom G6 Glucose Sensor. Dermatitis : contact, atopic, occupational, drug, . https://doi.org/10.1097/DER.0000000000000767
Mowitz, Martin, et al. "Further Evidence of Allergic Contact Dermatitis Caused by 2,2'-Methylenebis(6-tert-Butyl-4-Methylphenol) Monoacrylate, a New Sensitizer in the Dexcom G6 Glucose Sensor." Dermatitis : contact, atopic, occupational, drug vol. (2021). doi: https://doi.org/10.1097/DER.0000000000000767
Mowitz M, Lejding T, Ulriksdotter J, Antelmi A, Bruze M, Svedman C. Further Evidence of Allergic Contact Dermatitis Caused by 2,2'-Methylenebis(6-tert-Butyl-4-Methylphenol) Monoacrylate, a New Sensitizer in the Dexcom G6 Glucose Sensor. Dermatitis. 2021 Jun 11; doi: 10.1097/DER.0000000000000767. Epub 2021 Jun 11. PMID: 34115662.
Copy Download .nbib Format: NLM
Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors.

International journal of molecular sciences

Havránková E, Garaj V, Mascaretti Š, Angeli A, Soldánová Z, Kemka M, Motyčka J, Brázdová M, Csöllei J, Jampílek J, Supuran CT.
PMID: 35008657
Int J Mol Sci. 2021 Dec 26;23(1). doi: 10.3390/ijms23010231.

A series of 1,3,5-triazinyl aminobenzenesulfonamides substituted by aminoalcohol, aminostilbene, and aminochalcone structural motifs was synthesized as potential human carbonic anhydrase (hCA) inhibitors. The compounds were evaluated on their inhibition of tumor-associated hCA IX and hCA XII, hCA VII isoenzyme...

Cite
Havránková E, Garaj V, Mascaretti Š, et al. Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors. Int J Mol Sci. 2021;23(1)doi: 10.3390/ijms23010231.
Havránková, E., Garaj, V., Mascaretti, �. �., Angeli, A., Soldánová, Z., Kemka, M., Motyčka, J., Brázdová, M., Csöllei, J., Jampílek, J., & Supuran, C. T. (2021). Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010231
Havránková, Eva, et al. "Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors." International journal of molecular sciences vol. 23,1 (2021). doi: https://doi.org/10.3390/ijms23010231
Havránková E, Garaj V, Mascaretti Š, Angeli A, Soldánová Z, Kemka M, Motyčka J, Brázdová M, Csöllei J, Jampílek J, Supuran CT. Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors. Int J Mol Sci. 2021 Dec 26;23(1). doi: 10.3390/ijms23010231. PMID: 35008657; PMCID: PMC8745223.
Copy Download .nbib Format: NLM
207.2: Favorable 5-year Follow Up Outcomes After Islet Transplantation in Patients With Type 1 Diabetes Mellitus at University of Chicago.

Transplantation

Bachul P, Borek P, Anteby R, Generette GS, Basto L, Perea L, Wang LJ, Golab K, Tibudan M, Perez-Gutierrez A, Barth R, Fung J, Witkowski P.
PMID: 34908299
Transplantation. 2021 Dec 01;105(12):S3. doi: 10.1097/01.tp.0000804288.00839.c4.

No abstract available.

Cite
Bachul P, Borek P, Anteby R, et al. 207.2: Favorable 5-year Follow Up Outcomes After Islet Transplantation in Patients With Type 1 Diabetes Mellitus at University of Chicago. Transplantation. 2021;105(12):S3doi: 10.1097/01.tp.0000804288.00839.c4.
Bachul, P., Borek, P., Anteby, R., Generette, G. S., Basto, L., Perea, L., Wang, L. J., Golab, K., Tibudan, M., Perez-Gutierrez, A., Barth, R., Fung, J., & Witkowski, P. (2021). 207.2: Favorable 5-year Follow Up Outcomes After Islet Transplantation in Patients With Type 1 Diabetes Mellitus at University of Chicago. Transplantation, 105(12), S3. https://doi.org/10.1097/01.tp.0000804288.00839.c4
Bachul, Piotr, et al. "207.2: Favorable 5-year Follow Up Outcomes After Islet Transplantation in Patients With Type 1 Diabetes Mellitus at University of Chicago." Transplantation vol. 105,12 (2021): S3. doi: https://doi.org/10.1097/01.tp.0000804288.00839.c4
Bachul P, Borek P, Anteby R, Generette GS, Basto L, Perea L, Wang LJ, Golab K, Tibudan M, Perez-Gutierrez A, Barth R, Fung J, Witkowski P. 207.2: Favorable 5-year Follow Up Outcomes After Islet Transplantation in Patients With Type 1 Diabetes Mellitus at University of Chicago. Transplantation. 2021 Dec 01;105(12):S3. doi: 10.1097/01.tp.0000804288.00839.c4. PMID: 34908299.
Copy Download .nbib Format: NLM
Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action.

European journal of medicinal chemistry

Tanini D, Carradori S, Capperucci A, Lupori L, Zara S, Ferraroni M, Ghelardini C, Mannelli L, Micheli L, Lucarini E, Carta F, Angeli A, Supuran CT.
PMID: 34507012
Eur J Med Chem. 2021 Dec 05;225:113793. doi: 10.1016/j.ejmech.2021.113793. Epub 2021 Aug 23.

Platinum-based chemotherapy is widely used for the treatment of different tumors but is associated with serious side effects, among which neuropathic pain. Carbonic anhydrase (CA, EC 4.2.1.1) inhibitors have recently been validated as therapeutic agents in neuropathic pain and...

Cite
Tanini D, Carradori S, Capperucci A, et al. Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action. Eur J Med Chem. 2021;225:113793doi: 10.1016/j.ejmech.2021.113793.
Tanini, D., Carradori, S., Capperucci, A., Lupori, L., Zara, S., Ferraroni, M., Ghelardini, C., Mannelli, L., Micheli, L., Lucarini, E., Carta, F., Angeli, A., & Supuran, C. T. (2021). Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action. European journal of medicinal chemistry, 225113793. https://doi.org/10.1016/j.ejmech.2021.113793
Tanini, Damiano, et al. "Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action." European journal of medicinal chemistry vol. 225 (2021): 113793. doi: https://doi.org/10.1016/j.ejmech.2021.113793
Tanini D, Carradori S, Capperucci A, Lupori L, Zara S, Ferraroni M, Ghelardini C, Mannelli L, Micheli L, Lucarini E, Carta F, Angeli A, Supuran CT. Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action. Eur J Med Chem. 2021 Dec 05;225:113793. doi: 10.1016/j.ejmech.2021.113793. Epub 2021 Aug 23. PMID: 34507012.
Copy Download .nbib Format: NLM
Challenges of virtual interviewing for surgical fellowships: a qualitative analysis of applicant experiences.

Surgical endoscopy

Anteby R, Sinyard RD, Jogerst KM, McKinley SK, Coe TM, Petrusa E, Phitayakorn R, Scott DJ, Brunt LM, Gee DW.
PMID: 34448935
Surg Endosc. 2021 Aug 27; doi: 10.1007/s00464-021-08691-9. Epub 2021 Aug 27.

BACKGROUND: The COVID-19 pandemic forced surgical fellowship programs to transition from in-person to remote applicant interviews; the virtual interviewing format presented new and unique challenges. We sought to understand applicants' perceived challenges to virtual interviewing for a surgical fellowship...

Cite
Anteby R, Sinyard RD, Jogerst KM, et al. Challenges of virtual interviewing for surgical fellowships: a qualitative analysis of applicant experiences. Surg Endosc. 2021;doi: 10.1007/s00464-021-08691-9.
Anteby, R., Sinyard, R. D., Jogerst, K. M., McKinley, S. K., Coe, T. M., Petrusa, E., Phitayakorn, R., Scott, D. J., Brunt, L. M., & Gee, D. W. (2021). Challenges of virtual interviewing for surgical fellowships: a qualitative analysis of applicant experiences. Surgical endoscopy, . https://doi.org/10.1007/s00464-021-08691-9
Anteby, Roi, et al. "Challenges of virtual interviewing for surgical fellowships: a qualitative analysis of applicant experiences." Surgical endoscopy vol. (2021). doi: https://doi.org/10.1007/s00464-021-08691-9
Anteby R, Sinyard RD, Jogerst KM, McKinley SK, Coe TM, Petrusa E, Phitayakorn R, Scott DJ, Brunt LM, Gee DW. Challenges of virtual interviewing for surgical fellowships: a qualitative analysis of applicant experiences. Surg Endosc. 2021 Aug 27; doi: 10.1007/s00464-021-08691-9. Epub 2021 Aug 27. PMID: 34448935; PMCID: PMC8393782.
Copy Download .nbib Format: NLM
Chronic uveitis in Gaucher's disease.

Ocular immunology and inflammation

Raz J, Anteby I, Livni N, Benezra D.
PMID: 22827202
Ocul Immunol Inflamm. 1993;1(1):119-24. doi: 10.3109/09273949309086547.

Thirty patients with Gaucher's disease have been examined in the authors' clinic; 29 of them suffered from the adult form and one had the juvenile type of the disease. The authors found intraocular abnormalities in four patients: three suffered...

Cite
Raz J, Anteby I, Livni N, et al. Chronic uveitis in Gaucher's disease. Ocul Immunol Inflamm. 1993;1(1):119-24doi: 10.3109/09273949309086547.
Raz, J., Anteby, I., Livni, N., & Benezra, D. (1993). Chronic uveitis in Gaucher's disease. Ocular immunology and inflammation, 1(1), 119-24. https://doi.org/10.3109/09273949309086547
Raz, J, et al. "Chronic uveitis in Gaucher's disease." Ocular immunology and inflammation vol. 1,1 (1993): 119-24. doi: https://doi.org/10.3109/09273949309086547
Raz J, Anteby I, Livni N, Benezra D. Chronic uveitis in Gaucher's disease. Ocul Immunol Inflamm. 1993;1(1):119-24. doi: 10.3109/09273949309086547. PMID: 22827202.
Copy Download .nbib Format: NLM
Author Correction: Regulation of the one carbon folate cycle as a shared metabolic signature of longevity.

Nature communications

Annibal A, Tharyan RG, Schonewolff MF, Tam H, Latza C, Auler MMK, Grönke S, Partridge L, Antebi A.
PMID: 34385439
Nat Commun. 2021 Aug 12;12(1):5025. doi: 10.1038/s41467-021-24840-z.

No abstract available.

Cite
Annibal A, Tharyan RG, Schonewolff MF, et al. Author Correction: Regulation of the one carbon folate cycle as a shared metabolic signature of longevity. Nat Commun. 2021;12(1):5025doi: 10.1038/s41467-021-24840-z.
Annibal, A., Tharyan, R. G., Schonewolff, M. F., Tam, H., Latza, C., Auler, M. M. K., Grönke, S., Partridge, L., & Antebi, A. (2021). Author Correction: Regulation of the one carbon folate cycle as a shared metabolic signature of longevity. Nature communications, 12(1), 5025. https://doi.org/10.1038/s41467-021-24840-z
Annibal, Andrea, et al. "Author Correction: Regulation of the one carbon folate cycle as a shared metabolic signature of longevity." Nature communications vol. 12,1 (2021): 5025. doi: https://doi.org/10.1038/s41467-021-24840-z
Annibal A, Tharyan RG, Schonewolff MF, Tam H, Latza C, Auler MMK, Grönke S, Partridge L, Antebi A. Author Correction: Regulation of the one carbon folate cycle as a shared metabolic signature of longevity. Nat Commun. 2021 Aug 12;12(1):5025. doi: 10.1038/s41467-021-24840-z. PMID: 34385439; PMCID: PMC8361093.
Copy Download .nbib Format: NLM
Leishmaniasis mimicking multiple myeloma.

International journal of laboratory hematology

Papakonstantinou I, Koumpis E, Fytsili E, Panteli A, Milionis H, Papoudou-Bai A, Kapsali E, Hatzimichael E.
PMID: 34322992
Int J Lab Hematol. 2021 Jul 29; doi: 10.1111/ijlh.13667. Epub 2021 Jul 29.

No abstract available.

Cite
Papakonstantinou I, Koumpis E, Fytsili E, et al. Leishmaniasis mimicking multiple myeloma. Int J Lab Hematol. 2021;doi: 10.1111/ijlh.13667.
Papakonstantinou, I., Koumpis, E., Fytsili, E., Panteli, A., Milionis, H., Papoudou-Bai, A., Kapsali, E., & Hatzimichael, E. (2021). Leishmaniasis mimicking multiple myeloma. International journal of laboratory hematology, . https://doi.org/10.1111/ijlh.13667
Papakonstantinou, Ioannis, et al. "Leishmaniasis mimicking multiple myeloma." International journal of laboratory hematology vol. (2021). doi: https://doi.org/10.1111/ijlh.13667
Papakonstantinou I, Koumpis E, Fytsili E, Panteli A, Milionis H, Papoudou-Bai A, Kapsali E, Hatzimichael E. Leishmaniasis mimicking multiple myeloma. Int J Lab Hematol. 2021 Jul 29; doi: 10.1111/ijlh.13667. Epub 2021 Jul 29. PMID: 34322992.
Copy Download .nbib Format: NLM
Showing 217 to 224 of 224 entries